Role of ischemia-modified albumin and total homocysteine in estimating symptomatic lacunar infarction in type 2 diabetic patients

Clinical Biochemistry

Volumn 44, Issue 16, 2011, Pages 1299-1303

  Ma, Shao gang ^a   Xu, Wei ^a   Wei, Chun ling ^a   Wu, Xiao juan ^a   Hong, Bing ^a   Wang, Zeng jun ^a   Hao, Hai rong ^a   Guo, Hui qin ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Cerebral infarction, lacunar; Diabetes mellitus, type 2; Ischemia modified albumin

Indexed keywords

HOMOCYSTEINE; ISCHEMIA MODIFIED ALBUMIN;

ADULT; AGED; ARTICLE; AUTOANALYZER; BLOOD LEVEL; BRAIN INFARCTION; BRAIN VENTRICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RELIABILITY; STATISTICAL SIGNIFICANCE;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HOMOCYSTEINE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; ROC CURVE; SERUM ALBUMIN; STROKE, LACUNAR;

EID: 80054084033     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.08.1136     Document Type: Article

References (35)

1. Lukovits T.G., Mazzone T., Gorelick T.M. Diabetes mellitus and cerebrovascular disease. Neuroepidemiology 1999, 18:1-14.
2. Mankovsky B.N., Ziegler D. Stroke in patients with diabetes mellitus. Diabetes Metab Res Rev 2004, 20(4):268-287.
3. Janghorbani M., Hu F.B., Willett W.C., Li T.Y., Manson J.E., Logroscino G., et al. Prospective study of type 1 and type 2 diabetes and risk of stroke subtypes: the Nurses' Health Study. Diabetes Care 2007, 30:1730-1735.
4. Lai S.L., Weng H.H., Lee M., Hsiao M.C., Lin L.J., Huang W.Y. Risk factors and subtype analysis of acute ischemic stroke. Eur Neurol 2008, 60(5):230-236.
5. Bejot Y., Catteau A., Caillier M., Rouaud O., Durier J., Marie C., et al. Trends in incidence, risk factors, and survival in symptomatic lacunar stroke in Dijon, France, from 1989 to 2006: a population-based study. Stroke 2008, 39:1945-1951.
6. Norrving B. Long-term prognosis after lacunar infarction. Lancet Neurol 2003, 2:238-245.
7. Jørgensen H.S., Nakayama H., Raaschou H.O., Gam J., Olsen T.S. Silent infarction in acute stroke patients. Prevalence, localization, risk factors, and clinical significance: the Copenhagen Stroke Study. Stroke 1994, 25:97-104.
8. Song Y.M. Distinct location of subcortical silent infarcts compared with symptomatic lacunar infarcts. J Neurol Sci 2009, 287:197-199.
9. Zhang J.H., Kohara K., Yamamoto Y., Nakura J., Tabara Y., Fujisawa M., et al. Genetic predisposition to neurological symptoms in lacunar infarction. Cerebrovasc Dis 2004, 17:273-279.
10. Khan U., Porteous L., Hassan A., Markus H.S. Risk factor profile of cerebral small vessel disease and its subtypes. J Neurol Neurosurg Psychiatry 2007, 78:702-706.
11. Seshadri S., Wolf P.A., Beiser A.S., Selhub J., Au R., Jacques P.F., et al. Association of plasma total homocysteine levels with subclinical brain injury: cerebral volumes, white matter hyperintensity, and silent brain infarcts at volumetric magnetic resonance imaging in the Framingham Offspring Study. Arch Neurol 2008, 65:642-649.
12. Brattström L., Lindgren A., Israelsson B., Malinow M.R., Norrving B., Upson B., et al. Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors. Eur J Clin Invest 1992, 22(3):214-221.
13. Wang X., Qin X., Demirtas H., Li J., Mao G., Huo Y., et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 2007, 369:1876-1882.
14. Lee M., Hong K.S., Chang S.C., Saver J.L. Efficacy of homocysteine-lowering therapy with folic acid in stroke prevention: a meta-analysis. Stroke 2010, 14:1205-1212.
15. Bar-Or D., Lau E., Winkler J.V. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med 2000, 19:311-315.
16. da Silva S.H., Hausen Bdos S., da Silva D.B., Becker A.M., de Campos M.M., Duarte M.M., et al. Characteristics of a nickel-albumin binding assay for assessment of myocardial ischaemia. Biomarkers 2010, 15:353-357.
17. Hjortshøj S., Kristensen S.R., Ravkilde J. Diagnostic value of ischemia-modified albumin in patients with suspected acute coronary syndrome. Am J Emerg Med 2010, 28:170-176.
18. Van Belle E., Dallongeville J., Vicaut E., Degrandsart A., Baulac C., Montalescot G. OPERA Investigators. Ischemia-modified albumin levels predict long-term outcome in patients with acute myocardial infarction. The French Nationwide OPERA study OPERA Investigators. Am Heart J 2010, 159:570-576.
19. Turedi S., Patan T., Gunduz A., Mentese A., Tekinbas C., Topbas M., et al. Ischemia- modified albumin in the diagnosis of pulmonary embolism: an experimental study. Am J Emerg Med 2009, 27:635-640.
20. Abboud H., Labreuche J., Meseguer E., Lavallee P.C., Simon O., Olivot J.M., et al. Ischemia-modified albumin in acute stroke. Cerebrovasc Dis 2007, 23:216-220.
21. Gunduz A., Turedi S., Mentese A., Altunayoglu V., Turan I., Karahan S.C., et al. Ischemia-modified albumin levels in cerebrovascular accidents. Am J Emerg Med 2008, 26:874-878.
22. Braffman B.H., Zimmerman R.A., Trojanowski J.Q., Gonatas N.K., Hickey W.F., Schlaepfer W.W. Brain MR: pathologic correlation with gross and histopathology 1.Lacunar infarction and Virchow-Robin spaces. AJR Am J Roentgenol 1988, 151:551-558.
23. Adams H.P., Bendixen B.H., Kappelle L.J., Biller J., Love B.B., Gordon D.L., et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of org 10172 in acute stroke treatment. Stroke 1993, 249:35-41.
24. Koubaa N., Nakbi A., Smaoui M., Abid N., Chaaba R., Abid M., et al. Hyperhomocysteinemia and elevated ox-LDL in Tunisian type 2 diabetic patients: role of genetic and dietary factors. Clin Biochem 2007, 40:1007-1014.
25. Kaefer M., Piva S.J., De Carvalho J.A., Da Silva D.B., Becker A.M., Coelho A.C., et al. Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clin Biochem 2010, 43:450-454.
26. Ukinc K., Eminagaoglu S., Ersoz H.O., Erem C., Karahan C., Hacihasanoglu A.B., et al. A novel indicator of widespread endothelial damage and ischemia in diabetic patients: ischemia-modified albumin. Endocrine 2009, 36:425-432.
27. Gunduz A., Mentese A., Turedi S., Karahan S.C., Mentese U., Eroglu O., et al. Serum ischaemia-modified albumin increases in critical lower limb ischaemia. Emerg Med J 2008, 25:351-353.
28. Mentese A., Mentese U., Turedi S., Gunduz A., Karahan S.C., Topbas M., et al. Effect of deep vein thrombosis on ischaemia-modified albumin levels. Emerg Med J 2008, 25:811-814.
29. Piwowar A., Knapik-Kordecka M., Warwas M. Comparison of the usefulness of plasma levels of oxidatively modified forms of albumin in estimating kidney dysfunction in diabetic patients. Clin Invest Med 2010, 33:E109.
30. Turk A., Nuhoglu I., Mentese A., Karahan S.C., Erdol H., Erem C. The relationship between diabetic retinopathy and serum levels of ischemia-modified albumin and malondialdehyde. Retina 2011, 31:602-608.
31. Piva S.J., Duarte M.M., Da Cruz I.B., Coelho A.C., Moreira A.P., Tonello R., et al. Ischemia-modified albumin as an oxidative stress biomarker in obesity. Clin Biochem 2011, 44:345-347.
32. Barter P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. Antiinflammatory properties of HDL. Circ Res 2004, 95:764-772.
33. Nobécourt E., Jacqueminet S., Hansel B., Chantepie S., Grimaldi A., Chapman M.J., et al. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia 2005, 48:529-538.
34. Kim J.S., Lee H.S., Park H.Y., Kim S.S., Kang H.G., Kim N.H., et al. Endothelial function in lacunar infarction: a comparison of lacunar infarction, cerebral atherosclerosis and control group. Cerebrovasc Dis 2009, 28:166-170.
35. Howard V.J., Sides E.G., Newman G.C., Cohen S.N., Howard G., Malinow M.R., et al. Changes in plasma homocyst(e)ine in the acute phase after stroke. Stroke 2002, 33:473-478.